National Comprehensive Cancer Network
Pharmacy Program:
Educational Events & Programs
NCCN Clinical Practice Guidelines in Oncology Symposium: Colon and Rectal Cancers
Highlights from a symposium hosted by Memorial Sloan-Kettering Cancer Center on September 23, 2008
Presenters
Case Study Presentation – Rectal Cancer
Andrea Cercek, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Surgical Approaches to Rectal Cancers
John M. Skibber, MD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Case Study Presentation – Adjuvant Therapy
Andrea Cercek, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Adjuvant Therapy for Locoregional Colon Cancer
Paul F. Engstrom, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Case Study Presentation – Advanced Disease
Andrea Cercek, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Therapy for Advanced Disease
Leonard Saltz, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Faculty Disclosure Statements
Andrea Cercek, MD
Dr. Cercek has disclosed that she has no financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the educational activity.
Dr. Cercek has indicated that her presentation will not include discussion of investigational or unlabeled uses of a product.
John M. Skibber, MD
Dr. Skibber has disclosed that he has no financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the educational activity.
Dr. Skibber has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Paul F. Engstrom, MD
Dr. Engstrom has disclosed that he has no financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the educational activity.
Dr. Engstrom has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Leonard Saltz, MD
Dr. Saltz has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the educational activity. He has served as a consultant for Bayer HealthCare; Delcath Systems; Genentech, Inc.; ImClone Systems Incorporated; Merck & Co., Inc; Pfizer Inc.; Roche Laboratories, Inc.; and YM BioScience Inc. He has also received grant/research support from Amgen Inc.; Bayer HealthCare; Bristol-Myers Squibb Company; Genentech, Inc.; ImClone Systems Incorporated; Merck & Co., Inc.; Pfizer Inc.; Roche Laboratories, Inc.; and Taiho Pharmaceuticals Co., Ltd.
Dr. Saltz has indicated that his presentation will include discussion of investigational or unlabeled uses of a product.
Program Overview
NCCN, drawing on the expertise of faculty from its 21 Member Institutions, has developed and maintains clinical practice guidelines addressing colon and rectal cancers as part of its complete library of NCCN Clinical Practice Guidelines in Oncology™.
The NCCN Colon and Rectal Cancers Guidelines provide sequential recommendations for the management of lower gastrointestinal malignancies. This program will present these algorithms and focus on new approaches that have been incorporated into the pathways, including advances in surgical technique, such as total mesorectal excision and transanal excision; combined radiation/chemotherapy adjuvant therapy for rectal carcinoma; and the integration of newer agents into the overall strategy for managing advanced disease.
Educational Objectives
Following this activity, participants should be able to:
- Outline the appropriate workup for patients with colon and rectal carcinomas
- List the different surgical approaches to management based on site and stage at presentation and indications for transanal surgery in rectal cancer
- State the role of pre- and postoperative radiation in combination with chemotherapy in the management of rectal cancer
- Describe the current status of adjuvant chemotherapy for stage II and III colon and rectal cancers
- Identify new management strategies for metastatic colon and rectal carcinomas
Intended Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.
Activity Instructions
Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than December 19, 2009. There is no fee for participating in this activity.
Accreditation Information
Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
NCCN designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
This activity is approved for 2.0 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.
Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
Release date: December 19, 2008
Expiration date: December 19, 2009
Commercial Support
Supported by educational grants from Amgen, Bristol-Myers Squibb, Genentech BioOncology, ImClone Systems Incorporated, Pfizer Inc, Roche, and sanofi-aventis US
E-mail
Print
Mark
|
|
|
|
|
|
|
||